Fixed-dose Combination of Torsemide and Mineralocorticoid Receptor Antagonists.

Agam Vora, Prakash Kumar, Nitin Zalte, Amarnath Sugumaran, Jaspal Arneja, Kamal Sharma, Rajeev Garg, Aparna Jaswal, Sunip Banerjee, Girish B Navasundi, Kumaresan Kannan, Bishwa Bhushan Bharti, Upendar Narayan Singh, Purnanand Aila

Journal: The Journal of the Association of Physicians of India 2024;72(9S):40-42

PMID: 39291574

View on PubMed

Abstract

The combination of torsemide and spironolactone presents a promising approach to managing conditions such as edema and hypertension. Torsemide, a loop diuretic, enhances diuresis by inhibiting sodium reabsorption in the kidneys, while spironolactone, a potassium-sparing diuretic and mineralocorticoid receptor antagonist (MRA), complements this effect by preventing potassium loss and offering additional cardiovascular benefits. This review examines clinical evidence supporting their combined effectiveness in treating fluid retention and improving outcomes in conditions like heart failure (HF). Given the limited research available, it is essential to carefully evaluate patient-specific factors. However, several side effects necessitate careful patient selection and monitoring. Moreover, optimizing dosing regimens is crucial to ensure the safety and efficacy of torsemide and MRAs in clinical settings.

Address: Senior Interventional Cardiologist, Department of Cardiology, Kolkata Heart Lung Centre, Kolkata, West Bengal, India, Corresponding Author.; Senior Consultant, Interventional Cardiologist, and Director Cathlab, Department of Cardiology, Apollo Hospitals, Bengaluru, Karnataka, India.; Chest Physician, Department of Medicine, Vora Clinic, Mumbai, Maharashtra, India.; Senior Interventional Cardiologist, Department of Cardiology, Arneja Heart and Multispeciality Hospital, Nagpur, Maharashtra, India.; Senior Interventional Cardiologist and Head, Department of Cardiology, SAL Hospital and Medical Institute, Ahmedabad, Gujarat, India.; Director and Cardiologist, Department of Cardiac Pacing and Electrophysiology, Fortis Escorts Heart Institute, Delhi, India.; Senior Consultant Cardiologist and Head, Department of Cardiology, Stanley Hospital and Medical College, Chennai, Tamil Nadu, India.; Senior Interventional Cardiologist, Department of Cardiology, RIMS Hospital, Ranchi, Jharkhand, India.; Senior Interventional Cardiologist and Director, Department of Cardiology, Ford Hospital and Research Centre, Patna, Bihar, India.; Associate Professor and Head, Department of Cardiology, Patna Medical College Hospital, Patna, Bihar, India.; Senior Interventional Cardiologist and HOD, Department of Cardiology, Aware Gleneagles Global Hospitals, Hyderabad, Telangana, India.; Consultant Cardiologist, Department of Cardiology, Purna Heart Institute, Vijayawada, Andhra Pradesh, India.; Senior Team Lead, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.; Cluster Medical Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.

DOI: 10.59556/japi.72.0678

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-2658

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-GZMA-1

MeSH Terms: Humans, Mineralocorticoid Receptor Antagonists, Torsemide, Spironolactone, Heart Failure, Sulfonamides, Drug Combinations, Hypertension, Diuretics